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Epilepsies of early childhood are frequently resistant to therapy and often associated with cognitive and behav-
ioural comorbidity. Aetiology focused precision medicine, notably gene-based therapies, may prevent seizures and
comorbidities. Epidemiological data utilizing modern diagnostic techniques including whole genome sequencing
and neuroimaging can inform diagnostic strategies and therapeutic trials.
We present a 3-year, multicentre prospective cohort study, involving all children under 3 years of age in Scotland
presenting with epilepsies. We used two independent sources for case identification: clinical reporting and EEG re-
cord review. Capture-recapture methodology was then used to improve the accuracy of incidence estimates.
Socio-demographic and clinical details were obtained at presentation, and 24 months later. Children were exten-
sively investigated for aetiology. Whole genome sequencing was offered for all patients with drug-resistant epi-
lepsy for whom no aetiology could yet be identified. Multivariate logistic regression modelling was used to deter-
mine associations between clinical features, aetiology, and outcome.
Three hundred and ninety children were recruited over 3 years. The adjusted incidence of epilepsies presenting in
the first 3 years of life was 239 per 100 000 live births [95% confidence interval (CI) 216–263]. There was a socio-eco-
nomic gradient to incidence, with a significantly higher incidence in the most deprived quintile (301 per 100 000
live births, 95% CI 251–357) compared with the least deprived quintile (182 per 100 000 live births, 95% CI 139–233),
v2 odds ratio = 1.7 (95% CI 1.3–2.2). The relationship between deprivation and incidence was only observed in the
group without identified aetiology, suggesting that populations living in higher deprivation areas have greater
multifactorial risk for epilepsy. Aetiology was determined in 54% of children, and epilepsy syndrome was classified
in 54%. Thirty-one per cent had an identified genetic cause for their epilepsy.
We present novel data on the aetiological spectrum of the most commonly presenting epilepsies of early child-
hood. Twenty-four months after presentation, 36% of children had drug-resistant epilepsy (DRE), and 49% had glo-
bal developmental delay (GDD). Identification of an aetiology was the strongest determinant of both DRE and GDD.
Aetiology was determined in 82% of those with DRE, and 75% of those with GDD. In young children with epilepsy,
genetic testing should be prioritized as it has the highest yield of any investigation and is most likely to inform
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precision therapy and prognosis. Epilepsies in early childhood are 30% more common than previously reported.
Epilepsies of undetermined aetiology present more frequently in deprived communities. This likely reflects
increased multifactorial risk within these populations.
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Introduction
The epilepsies are a group of conditions defined by an ‘enduring
predisposition of the brain to generate epileptic seizures’.1,2
Epilepsies result from diverse aetiologies, including structural
brain lesions, as well as monogenic and polygenic variation.
Recent advances in both neuroimaging and genetic testing have
resulted in a significant increase in the proportion of epilepsies
that can be aetiologically resolved, particularly among epilepsies
that begin in early childhood.3 Precise clinical classification of epi-
lepsy syndrome, and identification of a genetic aetiology, helps
guide therapeutic strategy, exemplified by randomized controlled
trials in Lennox-Gastaut syndrome,4,5 and Dravet syndrome.6,7 For
the individually rare but severe epilepsies caused by large effect
mutations in a single gene, gene-directed therapy is a realistic
prospect.8
The epilepsies have a high incidence in early childhood. On a
population level, the highest age-specific incidences of 460 per
100 000 are observed in children under 5 years of age and in adults
over 65 years of age.9 A significant proportion (35%) of children
presenting with epilepsies in the first 3 years of life develop drug-
resistant seizures.10 These individuals are at high risk of cognitive
and behavioural comorbidity11 and of early mortality.12 Whilst
early age of onset, poor seizure control, and developmental
comorbidity are undoubtedly interrelated,10 the causal nature of
these relationships is not clear. Underlying aetiology is likely to
play a significant role in determining outcomes but has not previ-
ously been investigated at population level in the context of mod-
ern neuroimaging and genetic technology. We have established a
whole population cohort of children presenting with epilepsies
before the age of 3 years in Scotland. The aims of this study are to
describe the incidence and phenotypes of epilepsies in this age
group for a national cohort; to comprehensively investigate for
underlying causes; and to use this information to determine the
relationships between socio-economic status, aetiology, seizure
control and developmental outcome.
Materials and methods
Patients
This was a prospective cohort study involving the whole popula-
tion of Scotland (n = 5 424 800 for year 2017).13
Inclusion criteria included presentation (i) with recurrent (two
or more) unprovoked seizures; (ii) before child’s third birthday; (iii)
between 8 May 2014 and 7 May 2017.
Exclusion criteria included: (i) all—or all but one—epileptic seiz-
ures were considered provoked. This includes febrile seizures and
acute symptomatic seizures. Acute symptomatic seizures were
defined as epileptic seizures attributed to an identified transient
insult and resolving within 28 days of that insult. Examples of
transient insults include CNS infection, CNS parainfectious syn-
dromes such as acute disseminated encephalomyelitis (ADEM),
electrolyte disturbance, CNS infarct or haemorrhage, or CNS hyp-
oxic injury; and (ii) epilepsy diagnosis subsequently disproved.
Patient ascertainment
Two independent sources of case capture were used: (i) prospect-
ive recruitment via paediatricians, paediatric neurologists, and
epilepsy specialist nurses; and (ii) independent review of the
records of all children who had undergone EEG.
Prospective recruitment
Children were recruited from 20 regional paediatric departments
and four tertiary children’s hospitals, representing all centres
where children with seizures within the universal national
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healthcare system of Scotland are seen and assessed. Maximum
case ascertainment was ensured by weekly e-mail reminders
throughout the study period to a link clinician in each of the 24
centres and all 17 epilepsy specialist nurses in Scotland. Research
nurses throughout Scotland reviewed admissions to all intensive
care and high dependency units; and a national continuing educa-
tion programme maintained the profile of the study.
EEG review
There are eight paediatric neurophysiology departments in
Scotland. Details of all patients who undergo EEG is stored on elec-
tronic servers. The medical case records of all children who had
EEG during between 1 January 2014 and 31 December 2017, and
who were under 4 years of age at the time of EEG, were reviewed to
determine if they satisfied the inclusion and exclusion criteria.
Clinical information
Clinicians were required to complete a structured proforma at the
time of recruitment, giving clinical details in relation to the first
epileptic seizures, including age of child, seizure type classifica-
tion, cognitive and behavioural comorbidity, and any investigation
findings. The same clinical details were gathered from the case
records of patients ascertained through EEG record review.
Twenty-four months after initial presentation, the clinical
records of each patient were reviewed to determine epileptic syn-
drome classification, aetiology classification, and whether a diag-
nosis of drug-resistant epilepsy (DRE) or global developmental
disability (GDD) had been made. DRE was defined as ongoing epi-
leptic seizures despite two adequately trialled and tolerated anti-
epileptic drug (AED) regimens, or the prescription of a third AED
regimen due to lack of efficacy of two previous medications.14 GDD
was defined as delay 52 standard deviations (SD) below the mean
in two or more domains of development (gross motor, fine motor,
speech and language, social), as perceived by the managing phys-
ician.15 Epilepsy was classified as per the 2017 International
League Against Epilepsy (ILAE) position paper on classification of
the epilepsies.16
Aetiological investigations
All children without an already established aetiology for their epi-
lepsy were offered genetic testing on a 104-gene epilepsy panel.17
Patients who were negative on panel testing who had GDD were
tested for genomic copy number variants (CNVs) using chromo-
somal microarray. Patients negative on panel testing who had DRE
were offered trio whole genome sequencing (WGS). Neuroimaging
and EEG investigations were performed at the clinical discretion of
the managing physician.
Population data and deprivation scores
National Records of Scotland birth records13 were used to obtain
denominator data for births over the study period. Incidence esti-
mates were rounded to three significant figures and 95% confi-
dence intervals (CIs) were calculated using the Poisson
distribution. Participants were classified into five quintiles of the
Scottish Index of Multiple Deprivation (SIMD)18 based on their resi-
dent postcode at the time of their second unprovoked seizure.
Statistical analysis
To produce adjusted incidence estimates using capture recapture
methodology, assuming that our two ascertainment strategies
were independent, we used the following formula: (N1  N2) / N1+2,
where N1 is the number of cases identified through prospective re-
cruitment, N2 the number of cases identified through EEG review,
and N1+2 the number of cases identified through both ascertain-
ment strategies (the overlap).
Ninety-five per cent confidence intervals (CI) for incidence esti-
mates for epilepsy syndromes and aetiologies were obtained using
Poisson statistics. To investigate for associations between depriv-
ation [Scottish Index of Multiple Deprivation (SIMD) quintile] and
incidence of epilepsies, we used v2 test of trend and v2 test for dif-
ferences between quintiles 1 and 5.
IBMVR SPSSVR Statistics Version 26 was used to determine associ-
ations between clinical categorical variables. Univariate modelling
used Fisher’s exact test. Multivariate modelling used binary logis-
tic regression (Hosmer-Lemeshow test). Model construction was
informed by the findings from the univariate analysis, and is
described in detail where these data are presented in the ‘Results’
section.
Ethical approvals and consent
The study was approved by the West of Scotland NHS Research
Ethics Committee (REC number 13/WS/0299, IRAS ID 135019) and
the Scotland NHS National Research Ethics Committee (REC num-
ber 16/SS/0054, Protocol number GN15NE178, IRAS ID 170749).
Signed parental consent for gene panel testing, WGS, and pro-
spective follow-up, was obtained for participants.
Data availability
All individual case data used in the analysis is available in the
Supplementary material.
Results
Incidence of epilepsies presenting in the first 3 years
of life
Over the 3-year study period (May 2014 to May 2017), 390 patients
with epilepsies presenting in the first 3 years of life were identified
in Scotland. Two hundred and seventy-eight patients were
recruited to the prospective study. Two thousand four hundred
and two children under 4 years of age underwent EEG investiga-
tion between 1 January 2014 and 31 December 2017. After review of
their case records, we identified 355 patients satisfying the inclu-
sion criteria. Two hundred and forty-three patients were picked up
through both methodologies. Using a capture-recapture estimate,
the adjusted number of patients presenting with epilepsy in the
first 3 years of life was 405.
The mean birth rate in Scotland between 2011 and 2016 inclu-
sive was 56 490 per year and remained stable during this period
(range 54 488–58 590). Therefore, a denominator value of 169 500
was used as the estimated number of births over a 3-year period
2014–17.
From these data, we determined that the crude incidence of
epilepsies presenting in the first 3 years of life in this Scottish
population was 230 per 100 000 live births (95% CI 208–254) or 1
per 435 live births. Using capture recapture methodology, the
adjusted incidence was 239 per 100 000 live births (95% CI 216–263),
or 1 per 418 live births. The highest age-specific incidence was in
the 0–6 month age group, with incidence dropping in every subse-
quent 6-month group, before rising again in the 30–36-month
bracket (Fig. 1 and Supplementary Table 1).










We proceeded to investigate the relationship between epilepsy in-
cidence and deprivation based on the SIMD. Significantly higher
incidences were observed in the most deprived quintile of the
population, based on household residence location, compared
with the least deprived quintile. Incidence in the most deprived
quintile was 301 per 100 000 live births (95% CI 251–357) and in the
least deprived quintile was 182 per 100 000 live births (95% CI 139–
233). This was a significant difference [v2 odds ratio (OR) = 1.7 (95%
CI 1.3–2.2)]. There was also a significant trend, with higher inciden-
ces observed with increasing deprivation (v2 for trend, P = 0.01)
(Fig. 2A and Supplementary Table 2). When only those with an
identified aetiology were included in the same analysis there was
no association with deprivation (v2 for difference between quintile
1 and quintile 5, P = 0.26; v2 for trend, P = 0.5) (Fig. 2B and
Supplementary Table 2 ). The association with deprivation was
maintained when only those without an identified aetiology were
included. Here there was a significant difference in incidence be-
tween quintile 1 and quintile 5 [OR 2.3 (95% CI 1.4–2.8)] and a sig-
nificant trend across the quintiles (P = 0.005) (Fig. 2C and
Supplementary Table 2). There were no significant associations be-
tween SIMD quintile and any variables in relation to age or presen-
tation, seizure type, development of DRE/GDD, or aetiology
(Supplementary material). We investigated whether children in
lower deprivation quintiles were more extensively investigated by
MRI and genetic testing and this was not the case (Supplementary
material).
Classification
We next considered the clinical epilepsy classification. Two hun-
dred and nine of 390 (54%) of identified epilepsies were classified
clinically as either a developmental and epileptic encephalopathy
(DEE), a self-limited epilepsy, or another specific epilepsy
Figure 1 Incidence by age of presentation. (A) Incidence of epilepsies by age of presentation, per 100 000 live births. (B) Cumulative incidence of epi-
lepsies by age of presentation, per 100 000 live births.
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syndrome (Table 1). Infantile spasms syndrome was the most
common syndrome, with an incidence of 30.7 per 100 000 live
births (95% CI 22.9–40.2). As expected, there were higher frequen-
cies of DRE, GDD and mortality among those with epilepsies classi-
fied as DEE compared with those classified as self-limited
epilepsies. The incidences of a number of epilepsy syndromes that
only present in the first 3 years of life are presented in Table 1. All
11 patients diagnosed with Dravet syndrome had a de novo patho-
genic variant in the SCN1A gene.
Thirteen (3%) of children had died by 24-month follow-up. All
of these had been diagnosed with GDD prior to death. Ten of those
that died had been diagnosed with DRE. Mortality was 8% among
children classified as having DEE.
Aetiology and investigations
We identified an underlying aetiology in 211/390 patients (54%),
and in 143/225 (64%) of those who presented in the first year of life.
For 79 patients the underlying aetiology was already established
prior to presentation with seizures. Although a total of 71 patients
(18%) had a structural aetiology identified through neuroimaging,
for 53 (75%) of these this had been identified before the
Figure 2 Incidence and deprivation. (A) Incidence of epilepsies by SIMD category, per 100 000 live births. (B) Incidence of epilepsies with aetiology
by SIMD category, per 100 000 live births. (C) Incidence of epilepsies without aetiology by SIMD category, per 100 000 live births.
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presentation with seizures, including four of the six patients in the
cohort diagnosed with tuberous sclerosis.
For those who did not have an established aetiology prior to pres-
entation with seizures, 270/311 (87%) had gene panel testing, 216/311
(69%) had chromosomal microarray, and 267/311 (86%) brain MRI.
The diagnostic yields for investigations instigated after presentation
with seizures were: 82/270 (30%) for gene panel testing; 18/216 (8%)
for chromosomal microarray, and 18/267 (7%) for brain MRI. The
overall contribution of each testing modality to diagnostic yield is
shown in Fig. 3, in which we have indicated whether aetiological
diagnosis was made before or after presentation with seizures.
Considering structural causes, the most common identified
were: congenital brain malformation (n = 27 patients), white
matter injury or intraventricular haemorrhage associated with
preterm delivery (n = 10), hypoxic ischaemic perinatal injury (n =
10), perinatal stroke (n = 7), Sturge-Weber syndrome (n = 4), trau-
matic brain injury (n = 3), and brain tumour (n = 3).
The most common genetic causes were: PRRT2 (n = 17 patients),
SCN1A (n = 12), KCNQ2 (n = 9), SLC2A1 (n = 8), tuberous sclerosis
(TSC1 or TSC2) (n = 6), and trisomy 21 (n = 6).
Twenty-eight patients with no definitive aetiology after neuroi-
maging and gene panel testing underwent trio WGS.
Six patients had diagnostic results from WGS (Supplementary
material). Diagnoses made through WGS were pathogenic SNVs in
NEXMIF, CACNA1G, CHD4, POLR1A, NIPBL (all de novo), and CNTNAP1
(autosomal recessive). We analysed the WGS data for pathogenic
Figure 4 Aetiological spectrum of the more common epilepsy syndromes of early childhood, showing the total yield from aetiological investigations
for each epilepsy syndrome. DEE = developmental and epileptic encephalopathy.
Figure 3 Diagnostic yield from investigations carried out before and after presentation with seizures. A 104 gene epilepsy panel provided the diagno-
sis for 39% of the total with aetiology, and for 63% of those whose investigations were initiated after presentation with seizures. Neuroimaging after
presentation with seizures only provided an aetiological diagnosis in 9% of the total with aetiology.
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CNVs and for rare intronic variants in established epilepsy genes, but
did not find any. The aetiological spectrum of the more common epi-
lepsy syndromes diagnosed in this cohort is presented in Fig. 4.
One hundred and thirty-three of 390 patients (34%) had an epi-
lepsy with a defined genetic aetiology, including trisomies and
pathogenic chromosomal microdeletions/duplications. The overall
incidence of epilepsies with defined genetic aetiology was 178 per
100 000 live births (95% CI 66–93), or 1 per 952 live births.
Sixty-seven (66%) of all single gene diagnoses involved one of
the nine most frequently implicated genes (PRRT2, SCN1A, KCNQ2,
SLC2A1, TSC2, CDKL5, DEPDC5, PCHD19 and SLC6A1).
Univariate analysis of associations between clinical
features, aetiology and outcome
We next considered the relationships between aetiology, clinical
features at presentation, and outcome. In this study cohort, 24
months after initial presentation, we found that 139 children had
DRE (36%) and 193 had GDD (49%). A further 26 children (7%) had
behavioural problems, motor disorder, speech and language delay,
or features of autism spectrum disorder but did not satisfy the cri-
teria for a diagnosis of GDD. An aetiology was identified in 114/139
(82%) patients with DRE, and in 144/193 (75%) of patients with
GDD.
On univariate analysis, using a P-value of 50.001 to correct for
multiple testing, we determined that presentation with seizures
512 months and identification of genetic aetiology were both
associated with DRE. Presentation with epileptic spasms and iden-
tification of structural aetiology were both associated with GDD
(Table 2).
The strongest association with good outcome was the failure to
identify any aetiology, despite extensive investigation (Table 2). Of
the 180 children with unknown aetiology 25 (14%) had DRE, and 49
(27%) had GDD, at 24-month follow-up.
Table 2 Univariate analysis of associations between presenting seizure, age at presenting seizure, deprivation, aetiology, and DRE,
GDD and mortality
Total DRE P-value; OR
(95% CI) for DRE
GDD P-value; OR
(95% CI) for GDD
Death
Sex
Male 207 74 (36%) n.s. 104 (50%) n.s. 6 (3%)
Female 183 65 (36%) n.s. 89 (49%) n.s. 7 (4%)
Presenting seizure classification
Generalized seizure 140 35 (25%) 0.0013; 0.47 (0.30–0.74)# 47 (34%) 0.000003; 0.36 (0.24–0.55)## 3 (2%)
Generalized tonic-clonic seizure 97 22 (23%) 30 (31%) 1 (1%)
Myoclonic seizure 22 7 (32%) 9 (41%) 0 (0%)
Absence seizure 10 2 (20%) 3 (30%) 0 (0%)
Tonic seizure 8 2 (25%) 3 (38%) 2 (25%)
Atonic seizure 3 2 (67%) 2 (67%) 0 (0%)
Focal seizure 193 75 (39%) n.s. 100 (52%) n.s. 9 (5%)
Epileptic spasms 52 27 (52%) 0.012; 2.18 (1.20–3.93)* 42 (81%) 0.0000023; 4.92 (2.39–10.15)** 1 (2%)
Unclassified seizure 5 2 (40%) n.s. 4 (80%) n.s. 0 (0%)
Age at second unprovoked seizure
512 months 225 97 (43%) 0.00040; 2.22 (1.43–3.44)** 122 (54%) 0.032; 1.57 (1.05–2.35)* 10 (4%)
12–24 months 91 21 (23%) 0.0057; 0.46 (0.27–0.79)# 37 (41%) n.s. 2 (2%)
24–36 months 74 21 (28%) n.s. 34 (46%) n.s. 1 (1%)
SIMD quintile
1 (highest deprivation) 122 48 (39%) n.s. 61 (50%) n.s. 4 (3%)
2 81 28 (34%) n.s. 40 (50%) n.s. 1 (1%)
3 65 19 (30%) n.s. 30 (46%) n.s. 2 (3%)
4 66 23 (35%) n.s. 28 (42%) n.s. 3 (5%)
5 (lowest deprivation) 56 21 (38%) n.s. 34 (61%) n.s. 3 (5%)
Aetiological classification
Genetic (only) 100 54 (54%) 0.000012; 2.83 (1.77–4.52)** 59 (59%) 0.028; 1.68 (1.06–2.66)* 2 (2%)
Genetic-structural 27 14 (52%) n.s. 24 (89%) 0.000013; 9.18 (2.72–31.04)** 3 (10%)
Genetic-metabolic 4 3 (75%) n.s. 4 (100%) n.s. 4 (100%)
Genetic-metabolic-structural 2 2 (100%) n.s. 1 (50%) n.s. 1 (50%)
Structural (only) 71 37 (52%) 0.0017; 2.32 (1.37–3.90)* 53 (75%) 0.0000030; 3.76 (2.11–6.71)** 1 (1%)
Structural-metabolic 3 1 (33%) n.s. 1 (33%) n.s. 0 (0%)
Structural-infectious 2 2 (100%) n.s. 2 (100%) n.s. 0 (0%)
Metabolic only 1 0 (0%) n.s. 0 (0%) n.s. 0 (0%)
Structural-immune 1 1 (100%) n.s. 1 (100%) n.s. 0 (0%)
Unknown 179 25 (14%) 7.07  10–17; 0.14 (0.084–0.23)## 48 (27%) 7.96  10–17; 0.17 (0.11–0.26)## 3 (2%)
Outcome by 24 months after presentation
DRE 139 116 (83%) 1.23  10–24; 11.40 (6.76–19.20)** 10 (7%)
GDD 193 116 (60%) 1.23  10–24; 11.40 (6.76–19.20)** 13 (7%)
Total 390 139 (36%) 193 (49%) 13 (3%)
Probabilities based on Fisher’s Exact probability test (two-tailed). n.s. = not significant.
*Positive association, significant using a P-value 5 0.05.
**Positive association, significant using a P-value of 50.001 (corrected for multiple testing  50).
#Negative association, significant using a P-value 5 0.05.
##Negative association, significant using a P-value of 50.001 (corrected for multiple testing  50).
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A group of patients with particularly good outcomes was those
who presented with generalized tonic-clonic seizures and who
had no identifiable aetiology. Among 62 such patients, three (5%)
had DRE and nine (15%) had GDD.
Even among children presenting with infantile spasms, a pres-
entation with typically guarded prognosis, a significant association
between aetiology and outcome was observed. Fifty-two children
presented with infantile spasms, 38 (73%) of whom had an aeti-
ology identified (15 structural, 13 structural-genetic, 10 genetic,
one metabolic-genetic). Among those with aetiology, 33 (87%) had
GDD and 23 (61%) had DRE. Among those without aetiology, 9/14
had GDD (64%) and 4/14 (29%) had DRE. The difference in fre-
quency of DRE was statistically significant [Fisher’s exact test,
P = 0.04, OR 3.8 (95% CI 1.0–14.5)] but the difference in frequency of
GDD was not (Fisher’s exact test, P4 0.1). A more sensitive study
with larger numbers would be required to determine the influence
of aetiology on developmental outcomes in patients with infantile
spasms.
There was a very strong association between DRE and GDD (OR
11.40, 95% CI 6.76–19.20). We therefore considered whether DRE was
on the causal pathway between aetiology and GDD. Two possible
explanations may explain this relationship. It may be that common
factors, primarily underlying aetiology, strongly determine both
these outcomes. Alternatively, it may be that frequent seizures in the
DRE population directly lead to GDD. To exclude known aetiology as
a confounder in this relationship we looked at the relationship
Table 3 Multivariate analysis of associations between presenting seizure type, age at presenting seizure, aetiology, DRE, and GDD
Dependent variable Covariates Wald statistic P-value OR (95% CI)
GDD Age at presentation, days 0.18 0.668 No significant association
Identification of aetiology 22.6 0.000* 3.4 (2.1–5.7)
Focal seizures or spasms 4.5 0.033 No significant association
DRE 50.0 0.000* 7.2 (4.2–12.5)
DRE Age at presentation, days 3.3 0.069 No significant association
Identification of aetiology 22.5 0.000* 4.0 (2.2–7.0)
Focal seizures or spasms 0.03 0.860 No significant association
GDD 50.4 0.000* 7.3 (4.2–12.7)
Focal seizures or spasms Age at presentation, days 9.0 0.003* 1.001 (1.000–1.002)
Identification of aetiology 10.3 0.001* 2.3 (1.4–3.7)
DRE 0.006 0.936 No significant association
GDD 4.5 0.034 No significant association
Identification of aetiology Age at presentation, days 7.4 0.006* 1.001 (1.000–1.002)
Focal seizures or spasms 10.3 0.001* 2.2 (1.4–3.7)
DRE 22.1 0.000* 4.0 (2.4–7.1)
GDD 22.8 0.000* 3.4 (2.2–5.7)
*Positive association, significant using a P-value of 50.0125 (corrected for multiple testing  4)
Figure 5 Aetiology as the main driver of epilepsy severity and the key to effective treatment. (A) Correlation network, demonstrating interrelation-
ships between aetiology, age, seizure type, GDD and DRE. Thickness of arrow represents strength of relationship (Wald statistic on binomial regres-
sion model). Outcomes were strongly determined by aetiology. (B) Early identification of aetiology may allow prompt initiation of aetiology directed
therapy and thereby improve outcomes.
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between DRE and GDD in the group of children without aetiology
identified (n = 179). In this group, 25 children had DRE, of whom 19
(76%) had GDD. Among the 154 children without DRE, 29 had GDD
(19%). The association between DRE and GDD remained significant in
this group (OR 16.4, 95% CI 5.6–47.5). These data confirm that known
aetiology is not the only determinant of developmental outcome in
young children with epilepsies, and suggest that frequent epileptic
seizure activity may contribute to adverse developmental outcome.
Multivariate analysis
We constructed binomial regression models including as inde-
pendent variables all the features that were found to be associated
with either DRE or GDD in the univariate analysis. These were: age
at presentation, seizure type at presentation, and whether any
aetiology had been identified. Age in days was coded as a continu-
ous variable. Seizure type was coded as a binary variable (‘general-
ized seizure’ versus ‘focal seizure or spasms’). Aetiology was coded
as a binary variable (‘aetiology identified’ versus ‘no aetiology
identified’). Both DRE and GDD were coded as binary variables
(‘present’ versus ‘absent’). We then carried out sequential binomial
multivariate regression analyses with seizure type, aetiology, DRE
and GDD as dependent variables, respectively (Table 3). In Fig. 5,
we have graphically represented the strength of associations be-
tween age at presentation, seizure type, aetiology, DRE and GDD.
The width of each arrow is proportional to the Wald statistic in the
regression model to represent the strength of association. The
strongest association was between DRE and GDD. Neither present-
ing seizure type, nor age at presentation with seizures, was associ-
ated with either DRE or GDD at 24 months. Identification of
aetiology was weakly associated with age at presentation and seiz-
ure type and was strongly associated with both DRE and GDD.
These findings suggest that aetiology is the primary determinant
of both DRE and GDD in epilepsy, and that the relationships be-
tween age at presentation and seizure type and DRE/GDD observed
in the univariate analyses are most likely to be confounded by de-
pendency of these variables on aetiology. In the multivariate ana-
lysis, the presence of known aetiology was associated with an OR
for GDD of 3.4 (95% CI 2.1–5.7) and an OR for DRE of 3.9 (95% CI 2.2–
7.0). The presence of DRE was associated with an OR of GDD of 7.2
(95% CI 4.2–12.5).
Discussion
Through this prospective cohort study, involving the entire popu-
lation of Scotland, we have been able to accurately describe the
epidemiology of the early childhood epilepsies in an economically
developed country with access to modern diagnostic technologies.
There are low levels of consanguinity in this population, and ac-
cess to universal healthcare is good. These data will be applicable
to other countries with similar demography.
We used two sources to identify children with epilepsies, and
employed capture-recapture methodology to improve the accuracy
of our incidence estimates. Two-source capture-recapture meth-
odology rests on the assumption that the two sources are fully in-
dependent. If there is a positive interaction between the two
sources (being identified by one source is associated with an
increased likelihood of being identified by the other source) then
capture-recapture figures will underestimate. If there is a negative
interaction between the two sources (being identified by one
source is associated with a decreased likelihood of being identified
by the other source) then the capture-recapture figures will over-
estimate. Negative interactions may occur in studies where mul-
tiple individuals are involved in notifying cases and these
individuals have knowledge about which cases have already been
reported. Positive interactions occur where one or more character-
istics of a case increases the likelihood that multiple sources will
identify them. Since our EEG case record review was done retro-
spectively and was not influenced by which cases had been pro-
spectively recruited, we would not expect a negative interaction.
We cannot exclude a positive interaction since it is conceivable
that recruiting clinicians may have been more aware of patients
who had undergone EEG. However, it is standard practice, and
reflected in Scottish national standards of care, that all children
diagnosed with epilepsy should have an EEG. In view of the possi-
bility of a small positive interaction between the two sources, our
incidence figures would best be considered minimum incidence
figures.
In a previous paper published in Brain in 201917 we reported the
genetic findings from a cohort that overlapped with that presented
in this paper. In the 2019 study we used prospective population-
based methodology to describe the incidence and phenotypic
spectrum of the most common single gene epilepsies of early
childhood, including PRRT2, SCN1A, KCNQ2 and SLC2A1. The key
methodological differences between the 2019 cohort and the pre-
sent one are as follows. First, in the present study we have only
included children who presented with epilepsies (i.e. two or more
unprovoked and afebrile seizures) during the period 8 May 2014 to
7 May 2017. Second, we included children who already had an
identified aetiology at the time that they presented with seizures.
Third, as well as using the prospective recruitment strategy via
paediatricians and paediatric neurologists, we employed a second
independent case ascertainment strategy by reviewing records of
all children who had been investigated using EEG. Finally, we took
genetic investigation further in the present study, by reporting the
results of karyotype and chromosomal microarray, and by offering
trio WGS to families of children with DRE of unknown aetiology
(n = 28). We have extended the data capture in the present study.
We include socio-demographic information using the SIMD, and
report information on seizure control, developmental progress,
and epilepsy classification 2 years after initial presentation for
each participant. The present study therefore gives comprehensive
incidence estimates for all epilepsies of early childhood, and refer-
ences these figures to aetiology, epilepsy syndrome classification,
and outcomes.
In common with other studies, we have shown that the epilep-
sies have a higher incidence in less economically advantaged
groups of society,19,20 but have for the first time extended this find-
ing to the early childhood-onset group. The fact that socio-eco-
nomic status is associated with epilepsy incidence at such an early
stage in life supports the conclusion that this trend is observed be-
cause low socio-economic status is a risk factor for epilepsies (so-
cial causation) rather than because epilepsies influence socio-
economic prospects (social drift).19 Subgroup analysis of our cohort
revealed that the association between deprivation and incidence
was observed among those who had epilepsies without aetiology
but not among those with aetiology. We therefore conclude that
the increased incidence of epilepsies observed in the more disad-
vantaged populations is not explained by an increased burden of
identifiable genetic causes, nor an increased burden of structural
causes such as hypoxic ischaemic encephalopathy, leukomalacia
from preterm delivery, or traumatic brain injury. This leaves us
with a theory that these populations may have increased multifac-
torial risk for epilepsies. Potential components of such multifactor-
ial risk could include early life stress,21,22 maternal smoking,23,24
and polygenic risk.25–27 Exploration of these risk factors, and their
relationship to both epilepsies and socio-economic deprivation are
important avenues for further research, and have implications for
resource management within health systems.
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In this study the incidence of epilepsies presenting in the first
year of life was 136 per 100 000 live births (95% CI 120–155), and in
the first 3 years of life was 239 per 100 000 live births (95% CI 216–
263). Using two independent sources of case-capture, we were able
to estimate the number of missing cases in this population, which
was 15 (4%). Previous estimates for the incidence of epilepsies in
the first year of life have all involved smaller denominator popula-
tions than the present study, and figures have ranged between 83
per 100 000 and 144 per 100 0009,28–32 In a 30-year retrospective re-
view of a cohort within the Rochester Epidemiology study (1980–
2009, n = 127) the incidence of epilepsies with onset in the first 3
years of life was estimated to be 163 per 100 000 live births.10 We
are likely to have identified higher incidences of early life epilep-
sies than previous studies due to our prospective recruitment
strategy. This resulted in greater inclusion of patients with self-
limited epilepsies, as evidenced by the high rate of PRRT2-associ-
ated epilepsies in this cohort. Importantly, given advances in gen-
etic and neuroimaging technology, none of the previously
published cohorts provide data on the extent to which participants
were investigated for aetiology, thereby limiting conclusions that
can be drawn on the relationship between aetiology and outcome.
In our cohort, a proactive approach to aetiological investigation
was taken, allowing an aetiology to be determined in 54% of cases.
If aetiology was not already known at the time of presentation
with seizures, clinicians had access to a 104 gene epilepsy panel.
Uptake of gene panel testing was 81%, and positive diagnostic yield
from this investigation was 33%. The most commonly identified
genetic aetiology in our cohort was PRRT2 (17 cases, 4% of the co-
hort). No other epilepsy cohort that has been subjected to system-
atic genetic testing has implicated PRRT2 in such a high proportion
of cases. In a study based in the USA, Lindy et al.33 reported 59
cases of PRRT2-associated epilepsy among a cohort of 8565
patients (0.7%). Since PRRT2-associated epilepsy is associated with
a good outcome in nearly all cases, there is little selection pressure
on this gene, and in 71% of cases in our study the variant was
inherited.17 It is possible that epilepsy-associated PRRT2 variants
are more prevalent in the Scottish population than other popula-
tions. However, the recurrent variant that we found in 475% (13/
17) of PRRT2 cases, c.649dup, p.Arg217Profs*8, has also been fre-
quently reported in other populations.34,35 We think the more like-
ly explanation for the high incidence of PRRT2 variants in our
study is that we present an unselected cohort of children with
early onset epilepsies, which includes those with mild phenotypes.
Other cohorts investigating genetic testing may have been rela-
tively depleted of patients with PRRT2-associated seizures, since
nearly all these children have a self-limited epilepsy phenotype.
The most common epilepsy syndrome in this cohort was in-
fantile spasms syndrome. Early recognition and treatment of in-
fantile spasms is important since there is a significant positive
correlation between treatment delay and adverse outcome.36
The strongest determinant of outcomes 24 months after pres-
entation was the identification of an aetiology. The relationship
between aetiology and outcome is in fact more nuanced than this,
since certain genetic aetiologies, most notably PRRT2 gene var-
iants, are associated with a very good prognosis.17 Where exten-
sive diagnostic testing is performed, families of children for whom
no aetiology can be identified can be reassured that the prognosis
is generally good for both seizure control and development.
That outcome is principally determined by aetiology has im-
portant implications when considering therapy development for
the epilepsies. The vast majority of those with either DRE or GDD
in this cohort had an identifiable aetiology. Aetiology-directed
therapy is already a reality in a number of childhood-onset genetic
epilepsies,37,38 and there is emerging evidence that early initiation
of appropriate therapy may improve not only seizure control, but
also cognitive outcome.39 Dravet syndrome, associated with de
novo pathogenic SCN1A variants, was the most common drug-re-
sistant genetic epilepsy in this cohort. The evidence for efficacy of
the recently repurposed drug fenfluramine is highly encouraging
in this condition.7 For parents of children affected by severe epi-
lepsies, cognitive and behavioural comorbidities may be stronger
determinants of quality of life than seizure frequency.40–42 It is im-
portant that therapeutic trials look at more holistic outcomes than
purely seizure control,37 as exemplified by the ICISS trial for chil-
dren with infantile spasms syndrome.43 Gene-corrective therapies
have already entered the clinical domain for a number of severe
neurological disorders of early childhood44 and are rapidly being
developed for the epilepsies. Appraisal of their efficacy will be de-
pendent on good quality prospective epidemiological data.
Conclusions
One in 400 children will be diagnosed with an epilepsy before their
third birthday. There is a clear social gradient to the incidence of
early childhood epilepsies, meaning that greater epilepsy-related
resources will be required in regions with high deprivation.
With modern neuroimaging and genetic techniques an aeti-
ology can be identified in more than 50% of patients. Genetic epi-
lepsies comprise the largest aetiological group. Identification of
aetiology strongly correlates with outcomes, in terms of both seiz-
ure control and development.
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